Overcoming Cancers Resistant to HER-2 Antibodies 1st Edition

Overcoming Cancers Resistant to HER-2 Antibodies, 1st Edition by Benjamin Bonavida delivers a clear, authoritative guide for clinicians, researchers, and graduate students confronting the urgent challenge of HER-2 antibody resistance. This compelling volume opens with a concise overview of the clinical impact of HER-2–positive cancers and immediately frames why resistance to trastuzumab and other HER-2–targeted therapies has become a pivotal obstacle in modern oncology.

Inside, Bonavida synthesizes molecular mechanisms—signal transduction alterations, receptor crosstalk, tumor heterogeneity, and immune-evasion pathways—into practical insights. Carefully explained experimental evidence and translational strategies illuminate combination therapies, novel antibody formats, small-molecule inhibitors, and immune-modulating approaches that are shaping next-generation treatment paradigms. Each chapter balances rigorous science with clinical relevance, making complex topics accessible without compromising depth.

Readers will appreciate the book’s emphasis on biomarker-driven decision making, resistance monitoring, and actionable approaches for overcoming therapeutic failure. Written for the global oncology community, this edition supports practitioners across North America, Europe, Asia-Pacific, and beyond who are seeking evidence-based strategies to improve patient outcomes in HER-2–driven malignancies.

Whether you are an oncologist updating your clinical toolkit, a researcher designing translational studies, or a student building a foundation in targeted therapy, Bonavida’s work offers practical direction and fresh perspectives. Add this essential resource to your professional library and stay at the forefront of managing and reversing resistance to HER-2 antibodies worldwide.

Note: eBooks do not include supplementary materials such as CDs, access codes, etc.